GLP-1 drugs and hair loss: what the trials found

The short answer

Yes, more often than the marketing suggests and less dramatically than the internet suggests. On the obesity labels it is a listed trial side effect, roughly three to six percent against one percent on placebo. It is almost entirely shedding, it starts about two months in, and it is usually temporary.

GLP-1 receptor agonists are copies of a gut hormone called GLP-1 (glucagon-like peptide 1), engineered to last far longer in the body than the real thing. Semaglutide is sold as Ozempic for type 2 diabetes and as Wegovy for weight management. Tirzepatide is sold as Mounjaro and Zepbound for the same two purposes. Same molecule, different brand, and, as it turns out, a different label.

Hair loss is printed in the clinical trial side effect table on the Wegovy label [1] and on the Zepbound label [2], with a percentage next to it. On the Ozempic [3] and Mounjaro [4] labels, the ones for diabetes, alopecia (the medical word for hair loss) appears only in the postmarketing section, which is the part of a label that collects reports from people after approval and states in its own preamble that because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

That gap is the most useful fact in this article, and almost nobody quotes it. It is not that the diabetes drug is safe for hair and the obesity drug is not. It is the same compound. What differs is how much weight the people in each trial programme actually lost, and the two molecules get there by different routes. For semaglutide it is partly a dose gap: Ozempic stops at 2 mg a week [3] while Wegovy goes to 2.4 mg and now 7.2 mg [1]. For tirzepatide it is not a dose gap at all, because Mounjaro and Zepbound run the identical 2.5 mg to 15 mg weekly range [4] [2]; what differs there is who was in the trials, since people with type 2 diabetes lose considerably less weight on the same dose. Both obesity labels say the connection out loud: hair loss adverse reactions were associated with weight reduction [1] [2].

The rest of this article is about how solid that "associated with weight reduction" sentence is, because the honest answer is: mostly solid, and not completely.

What the numbers on the labels are

On Wegovy, hair loss was reported by 3.3 percent on the 2.4 mg dose and 5.8 percent on the 7.2 mg dose, against 1.0 percent on placebo. On Zepbound the trial table reads 5, 4 and 5 percent across the three doses against 1 percent on placebo.

Take the semaglutide numbers first, because they show a pattern. Across a pool of three weight management trials, hair loss was reported by 3.3% of people on the 2.4 mg weekly dose and 1% of people on placebo [1]. In a pediatric trial the figures were 4% against nothing at all in the placebo group [1]. And in the trials of the higher 7.2 mg dose, the label reports 5.8% at 7.2 mg, 3.3% at 2.4 mg and 1.0% on placebo in the same set of studies [1]. Three doses, three rates, climbing in order.

That gradient is not an artefact of one label. A systematic review published in 2026 pulled the same pattern out of the wider literature and found it held across formulations: in a trial of a 50 mg daily oral semaglutide tablet for weight loss, alopecia was reported in 23 of 334 treated participants against 9 of 333 on placebo, and a separate comparison found the increase only at that oral dose, with 1 case among 407 people on the 2.4 mg weekly injection [5]. The review's summary of the low diabetes-range doses, 0.25 to 2 mg weekly, is that they are rarely implicated at all [5].

Tirzepatide behaves differently, and the difference is worth noticing. The Zepbound trial table lists hair loss at 5% on 5 mg, 4% on 10 mg and 5% on 15 mg, against 1% on placebo [2]. There is no climb there. The same flatness shows up in the trial literature: pooled across the tirzepatide weight loss programme, alopecia was recorded in 5.4% of 2,183 treated participants and 0.9% of 2,221 placebo participants, with the rate essentially the same at every dose studied [5].

A drug whose lowest studied dose already produces about as much weight loss as a high dose of its competitor would be expected to look flat, and that is exactly the explanation the review offers [5]. It is the first hint that the thing driving this is not milligrams of drug.

Women report it, men mostly do not

The sex difference on the labels is far larger than the drug effect. In the Wegovy 7.2 mg trials, 8.4 percent of women reported hair loss against 0.2 percent of men. On Zepbound it was 7.1 percent of women against 0.5 percent of men. This is the single biggest split in the data.

Both obesity labels break their hair loss figures down by sex, and the split dwarfs everything else on the page. In the pool of three semaglutide weight management trials, the 3.3% headline number is 4% of women and 0.9% of men, against a placebo group that was 2% of women and no men at all [1]. In the 7.2 mg trials the same breakdown reads 8.4% of women and 0.2% of men on the high dose, and 5.4% of women and no men on 2.4 mg [1]. Tirzepatide is the same shape: 7.1% of women against 0.5% of men on Zepbound, with a placebo group at 1.3% of women and no men [2].

Independent work points the same way. A preprint cohort study comparing semaglutide against a different weight loss drug, bupropion-naltrexone, found the adjusted increase in risk reached significance only in women, at a hazard ratio of 2.08, while the male estimate was 0.86 with a confidence interval so wide it excluded nothing [5]. A cross-sectional survey of 254 people in Saudi Arabia who had used one of these injections for weight loss, 71.3% of them women, found men were substantially less likely to report hair loss, with an adjusted odds ratio of 0.36 [9].

Nobody has established why. The reviews are careful about this, and they list two explanations that both look plausible and are not mutually exclusive. Women in these trials lose more weight on average, and are more likely to be restricting calories alongside the drug, so the trigger may simply be larger [5]. Women are also more likely to notice diffuse thinning and to report it, which inflates every database that depends on someone raising their hand [5]. The label figures are the strongest evidence against reporting bias being the whole story, because trial investigators were collecting those events systematically rather than waiting to be told.

Is it the drug, or is it the weight loss?

This is the question the studies were designed around, and the answer changes with what you compare against. Against placebo it looks like the drug. Against bariatric surgery it looks like the weight loss. Against other diabetes drugs, in people barely losing weight, a smaller signal survives.

Start with the comparison that favours "it is the weight loss", because it is the strongest one. A large records-based study of more than 218,000 people taking these drugs for obesity found that tirzepatide carried a raised risk of telogen effluvium (the shedding kind of hair loss, explained in the next section) compared with other weight loss medications, at a hazard ratio of 2.65, but not compared with bariatric surgery [5]. Bariatric surgery also takes a large amount of weight off quickly, and the telogen effluvium that follows it is well documented [10]. A drug that matches surgery and beats pills is behaving like a weight loss intervention, not like a poison.

The same label data agrees. In the Wegovy trials, the reported hair loss rate among people who lost more than 20% of their body weight was 5.3%, against 2.5% for those who lost less than 20% [5]. The amount of weight lost predicts the hair loss better than the dose does.

Then comes the study that stops this from being the whole answer. A 2026 analysis in the BMJ used a design called target trial emulation, which takes routine medical records and analyses them as though they were a randomised trial that was never run, specifically to remove the bias you get from comparing users against non-users [7]. It looked at adults with type 2 diabetes, a group who lose comparatively little weight on these drugs, and compared people starting a GLP-1 against people starting a different class of diabetes drug. Against SGLT-2 inhibitors the hazard ratio for new hair loss was 1.37, and against DPP-4 inhibitors it was 1.68, with the effect specific to non-scarring types of hair loss [7].

Those are modest numbers on a low baseline, and the authors say so directly: the absolute risk is low [7]. But they are not zero, and they come from a population where "it is just the rapid weight loss" has much less room to operate. The fair summary is that weight loss explains most of this and probably not all of it.

Telogen effluvium, and the two month delay

Scalp hair is about 90 percent actively growing at any moment. A physical shock pushes a chunk of it into the resting phase early, and those hairs fall out roughly two to three months later. That delay is why the shedding tends to start well after the drug did.

Almost all of what gets described here is telogen effluvium, and it is worth understanding because its timing explains most of the confusion. Roughly 90% of the hairs on a scalp are in anagen, the active growing phase, at any given moment [8]. A physiological shock, and the classic list includes childbirth, major surgery, a high fever and sudden weight loss, pushes an abnormal share of those follicles out of growth and into telogen, the resting phase, ahead of schedule [8]. A resting hair does not fall immediately. It sits there for a couple of months and then sheds, which is why the visible loss arrives about two to three months after the thing that caused it [8].

The weight loss numbers that trigger it are uncomfortably close to what these drugs deliver. A Korean hospital reviewed 140 patients diagnosed with weight loss telogen effluvium over fifteen years and found the shedding occurred at a mean weight reduction of 15.21% of body weight, at a mean rate of 3.54 kg per month [8]. That is squarely inside the range these medicines are prescribed to achieve. The same cohort found women had triggered at a slower rate of loss than men, 3.14 against 5.03 kg per month, which is another route to the sex difference in the label figures [8].

Bariatric surgery gives the same picture from a different direction. Hair loss after weight loss surgery splits into an acute form within the first three or four months, which is telogen effluvium, and a chronic form beginning after six months, which is usually about nutrition [10]. Two different clocks, two different causes, and the reviews of GLP-1 hair loss expect exactly the same two patterns for the same reasons [5].

What the evidence does not show

There is no human evidence that these drugs attack hair follicles directly. The receptor biology, as far as anyone has traced it, points the other way. And the databases most often quoted as proof measure how often something gets reported, which is not the same as how often it happens.

Two things get overstated in both directions here, and it is worth naming them.

The first is the idea that the drug is doing something to your follicles. No human study shows a direct effect on the hair follicle [5]. GLP-1 receptors have been found in the skin of newborn mice around hair follicles, and the signalling pathways those receptors switch on in other tissues, if they did the same thing in a follicle, would be expected to promote hair growth rather than block it [5]. There are even scattered reports running the other way, of hair improving on these drugs in people whose hair loss was tied to metabolic disease [6]. That is not a claim these drugs grow hair. It is a reason to be sceptical of the "it damages the follicle" framing.

The second is the weight given to pharmacovigilance databases, which are the collections of side effect reports that regulators maintain. They are the source of most of the alarming headlines and they measure reporting, not incidence. Those analyses disagree with each other badly: reporting odds ratios for semaglutide across studies run from 1.24 to 2.46, tirzepatide from 0.83 to 1.73, liraglutide from 0.61 to 1.53, and one multi-database review found GLP-1 drugs were reported for hair loss more than other diabetes drugs while its formal signal tests came back negative [6]. A meta-analysis of randomised trials put the pooled figure at 6.0 cases per 1,000 patient-years against 0.8 on placebo, a risk ratio of 3.40, but with a confidence interval running from 1.18 to 9.81 and a heterogeneity statistic near 68% [5]. That is a real signal measured very imprecisely.

It is also worth knowing how thin the reporting is underneath the totals. One 2026 systematic review found that across the entire literature it could assemble, the type of hair loss was specified for only 112 patients in total, and that latency and sex differences were not well described in the studies at all [6]. When a 2024 commentary called for proper investigation of this question, it described the clinical evidence as sparse [11]. Two years on it is larger and still not clean.

What the dermatology literature says happens next

Telogen effluvium is self-limiting. The published expectation is improvement within three to six months once weight stabilises, no scarring, and no permanent damage to the follicle. Persistent shedding, patterned thinning or an itchy scalp are the signals that point somewhere else.

The reassuring part of this is well established and it is not a hedge. Telogen effluvium has a high rate of remission [12], and the 2026 counselling review states that there is no strong evidence of permanent follicular damage from these drugs, with improvement generally seen within three to six months once weight stabilises [5]. The label data is consistent with that: across the pooled Zepbound weight management trials, no treated participant discontinued because of hair loss, while one placebo participant did [2]. In the semaglutide 7.2 mg trials, one hair loss event led to permanent discontinuation, one to a temporary interruption and five to a dose reduction, with none of those actions taken in the 2.4 mg or placebo groups [1].

The same review sets out what dermatologists watch for, and it is a list of exceptions rather than a protocol. Shedding that persists beyond six to nine months, thinning that follows a pattern rather than being diffuse, or a scalp that is itchy or inflamed all point away from simple shedding and toward something that needs a diagnosis [5]. Where shedding continues, the described workup is a basic blood panel looking at iron stores, thyroid function and vitamin D, because the point is to rule out the other causes rather than to confirm the drug [5].

On prevention, the literature is consistent and unexciting. Because the trigger is the speed and size of the weight change and the calorie deficit underneath it, the levers described are a slower rate of loss and adequate protein and micronutrient intake, with iron, zinc, vitamin D, B12 and A named specifically [5]. Nutritional deficiencies show up in about half of bariatric surgery patients, which is why the same advice follows that procedure [10].

None of that is a reason to stop a prescribed medicine on your own, and it is not something a website can decide for you. It is a reason to expect the shedding if you are losing weight fast, to recognise it as the temporary kind, and to bring it to the person who prescribed the drug rather than to a forum.